Skip to main content

Table 1 Summary of the studies, which have identified the elevated ASPH expression in human tumor tissues

From: Aspartate β-hydroxylase as a target for cancer therapy

Study Tumor tissues Positive cases of studied samples (n/n) Detection method Antibody (recognized region of ASPH protein)
Lavaissiere et al., [3] Hepatocellular 4/10 IHC FB-50 Ab (N-terminus)
Cholangiocarcinoma 20/20
Breast 4/4
Colon 6/10
Palumbo et al., [35] Pancreatic adenocarcinoma 19/19 IHC FB-50 Ab (N-terminus)
Sepe et al., [30] Primitive neuroectodermal (medulloblastoma, neuroblastoma) 28/28 IHC FB-50 Ab (N-terminus)
Maeda et al., [36] Cholangiocarcinoma 42/50 IHC FB-50 Ab (N-terminus)
Cantarini et al., [37] Hepatocellular 13/15 IHC FB-50 Ab (N-terminus) or 15C7 Ab (catalytic domain)
  13/15 (7.5-fold higher level of mRNA compared to normal tissue) RT-qPCR  
Monte et al., [38] Hepatocellular 8/8 IHC FB-50 Ab (N-terminus)
  8/8 (7-fold higher level of mRNA compared to normal tissue) RT-qPCR  
Yang et al., [39] 19 types of tumor tissuesa 94/104 IHC mAb G3 hybridoma
Wang et al., [40] Hepatocellular 150/233 IHC Polyclonal
Dong et al., [41] Pancreatic cancer 101/104 IHC FB-50 mAb (N-terminus)
Tang et al., [32] Hepatocellular 71/140 RT-qPCR  
Lin et al., [42] Breast 127/141 IHC FB-50 Ab (N-terminus)
Ogawa et al., [43] Pancreatic ductal adenocarcinoma 162/166 IHC FB-50 Ab (N-terminus)
  1. aLiver, kidney, breast, cervical, ovarian, Fallopian tube, laryngeal, lung, thyroid, pancreatic, thymic, prostate, bladder, esophagus, gastric, gall bladder, colon, and rectum cancer and cholangiocarcinoma